CSBR earnings

HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni

HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or

HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024.First Quarter Highlights:Total revenue increased 12% to $14.1 millionMargin improved to 50%Adjusted EBITDA of $2.0 millionNet income of $1.3 millionRonnie Morris, CEO of Champions, commented, "As outlined on our year-end earnings call, we're cautiously optimistic that we've weathered the worst of the business downturn and we're poised to emerge leaner and stronger. Our first quarter's performance provided

HACKENSACK, NJ / ACCESSWIRE / September 9, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the first quarter ended July 31, 2024, on Wednesday, September 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 726315. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51258, or by access

Annual Revenue of $50.2 Million HACKENSACK, NJ / ACCESSWIRE / July 18, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a leader in the development of advanced preclinical oncology solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2024.Fourth Quarter Financial Highlights:Fourth quarter revenue increased 7% to $14 millionAdjusted EBITDA fourth quarter income of $884,000Fourth quarter gross margin on pharmacology services of 49%Fiscal Year 2024 Financial Highlights:Annual revenue of $50.2 million, a decrease of 7% year-over-yearFiscal Year 2024 adjusted EBITDA loss of $3.9 millionFiscal Year 2024 gross margin on pharmacology services of 42%Ro

HACKENSACK, NJ / ACCESSWIRE / July 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the fourth quarter and year-ended April 30, 2024, on Thursday, July 18, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 135832. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 50895, or b

HACKENSACK, NJ / ACCESSWIRE / March 12, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal 2024, ended January 31, 2024.Third Quarter and Recent Highlights:Third quarter revenue of $12.0 million, a decline of 6%Gross margin declined to 35%College of American Pathologists (CAP) has awarded accreditation to US-based laboratoryRonnie Morris, CEO of Champions, commented, "As discussed over the course of the year, we're navigating through a challenging economic environment, specifically in the biotech sector, that began approxima

HACKENSACK, NJ / ACCESSWIRE / March 6, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2024, on Tuesday, March 12, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 877-545-0523 (Domestic) or 973-528-0016 (International) and enter the access code 860900. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 50100, or by accessing the

HACKENSACK, NJ / ACCESSWIRE / December 12, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2024, ended October 31, 2023.Second Quarter and Recent Highlights:Second quarter revenue of $11.6 million, a decline of 19%Revised fiscal year 2024 revenue guidance to be generally in-line with last year's resultsStrong quarterly bookingsEuropean lab received ISO accreditation and ATS certificationHired Brady Davis as President to develop new strategic initiativesRonnie Morris, CEO of Champions, commented, "As discussed during our

HACKENSACK, NJ / ACCESSWIRE / December 4, 2023 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2023, on Tuesday, December 12, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 589886. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 49578, or by access

HACKENSACK, NJ / ACCESSWIRE / September 13, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its first quarter of fiscal 2024, ended July 31, 2023.First Quarter and Recent Highlights:First quarter revenue of $12.6 million, a decline of 9%Strong quarterly bookingsHosting Scientific Symposium in Boston, MA on September 26thRonnie Morris, CEO of Champions, commented, "As outlined on our year-end earnings call, the downturn in the economy, and specifically the biotech sector, was going to weigh on the Company in

HACKENSACK, NJ / ACCESSWIRE / September 11, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2023, on Wednesday, September 13, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 417178. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International

Record Annual Revenue of $53.9 MillionHACKENSACK, NJ / ACCESSWIRE / July 24, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2023.Fourth Quarter and Fiscal Year 2023 Financial and Recent Business Highlights:Fourth quarter revenue increased 2% to $13.1 millionRecord annual revenue of $53.9 million, an increase of 10% year-over-yearYear-over-year fourth quarter and annual bookings increase of 15%Announced the formation of our wholly owned bio-tech subsidiary,

HACKENSACK, NJ / ACCESSWIRE / July 20, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the fourth quarter and year ended April 30, 2023, on Monday, July 24, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 877-545-0523 (Domestic) or 973-528-0016 (International) and enter the access code 477670. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International)

HACKENSACK, NJ / ACCESSWIRE / March 15, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its third quarter of fiscal 2023, ended January 31, 2023.Third Quarter and Recent Highlights:Record quarterly bookingsQuarterly revenue of $12.8 millionAdjusted EBITDA loss of $1.6 million, driven by a $1 million increase in R&D for our target discovery programCommenced in-vivo efficacy testing for therapeutic hits on lead programsRonnie Morris, CEO of Champions, commented, "Our third quarter results were weaker than we'

HACKENSACK, NJ / ACCESSWIRE / March 13, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2023, on Wednesday, March 15, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 500542. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (Internation

HACKENSACK, NJ / ACCESSWIRE / December 13, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its second quarter of fiscal 2023, ended October 31, 2022.Second Quarter and Recent Highlights:Record quarterly revenue of $14.3 million, an increase of 21% year over yearAdjusted EBITDA of $686,000Discovery targets progressing along the development timeline; expectation to advance to preclinical phase testing in calendar 2023Ronnie Morris, CEO of Champions, commented, "We continued to deliver good financial results w

HACKENSACK, NJ / ACCESSWIRE / December 9, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the second quarter ended October 31, 2022, on Tuesday, December 13, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 877-545-0523 (Domestic) or 973-528-0016 (International) and enter the access code 541646. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International)

HACKENSACK, NJ / ACCESSWIRE / September 8, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its first quarter of fiscal 2023, ended July 31, 2022.First Quarter and Recent Highlights:Record quarterly revenue of $13.7 million, an increase of 22% year over yearAdjusted EBITDA of $450,000Record quarterly bookingsSeries of antibody hits established in Alloy Therapeutics partnershipRonnie Morris, CEO of Champions, commented, "We continued to deliver on our long-term vision in the first quarter by growing our servi

HACKENSACK, NJ / ACCESSWIRE / September 6, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2022, on Thursday, September 8, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 618777. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (Internati

Record Annual Revenue of $49.1 MillionHACKENSACK, NJ / ACCESSWIRE / July 21, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2022.Fourth Quarter and Fiscal Year 2022 Financial and Recent Business Highlights:Fourth quarter revenue increased 22% to $12.9 millionRecord annual revenue of $49.1 million, an increase of 20% year-over-yearAchieved high end of revenue guidance of 20%Gross margin improved to 52% for fiscal year 2022Adjusted EBITDA of $3.1 million for

HACKENSACK, NJ / ACCESSWIRE / March 15, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its third quarter of fiscal 2022, ended January 31, 2022.Third Quarter and Recent Highlights:Record quarterly revenue of $13.2 million, an increase of 22% year over yearReported adjusted EBITDA of $1.5 millionGross margin for the nine months ended January 31, 2022 improved to 52%Signed co-development discovery partnerships with Fannin Innovation Studio and GigamuneRonnie Morris, CEO of Champions, commented, "Our third qu

HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2022, on Tuesday, March 15, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 692343. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and e

Reported income from operations of $263,000HACKENSACK, NJ / ACCESSWIRE / December 13, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, today announced its financial results for its second quarter of fiscal 2022, ended October 31, 2021.Second Quarter and Recent Highlights:Record quarterly revenue of $11.8 million, an increase of 17% year over yearReported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $743,000Gross margin improved to 52%Ronnie Morris, CEO of Champions, commented, "We had another qu

HACKENSACK, NJ / ACCESSWIRE / December 6, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), leaders in transformative technology solutions utilized in oncology drug discovery and development will report its financial and operational results for the second quarter ended October 31, 2021, on Monday, December 13, 2021, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 877-545-0320 (Domestic) or 973-528-0002 (International) and enter the access code 694190.A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 43911, or by access

HACKENSACK, NJ / ACCESSWIRE / September 13, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), leaders in transformative technology solutions utilized in drug discovery and development, today announced its financial results for its first quarter of fiscal 2022, ended July 31, 2021.First Quarter and Recent Highlights:Record quarterly revenue of $11.3 million, an increase of 18% year over yearReported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $422,000Validated 6 therapeutic discovery targetsRonnie Morris, CEO of Champions, commented, "On our year-end earnings call, we outlined the transformative strategic vision for Champions with the ex

HACKENSACK, NJ / ACCESSWIRE / September 2, 2021 / Champions Oncology, Inc. (CSBR), leaders in transformative technology solutionsutilized in oncology drug discovery and development will report its financial and operational results for the first quarter ended July 31, 2021, on Monday, September 13, 2021, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 844-602-0380 (Domestic) or 862-298-0970 (International). A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 42751, or by accessing the Investors section of the company's

Record Annual Revenue of $41 MillionHACKENSACK, NJ / ACCESSWIRE / July 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in creating transformative technology solutions to be utilized in drug discovery and development, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2021.Fourth Quarter and Fiscal Year 2021 Financial and Recent Business Highlights:Record annual revenue of $41.0 million, an increase of 28% year-over-yearDeveloped in house computational target discovery expertise to discover novel therapeutic targetsContinued expansion of our Lumin SaaS platformRonnie Morris, CEO of Champions, commented, "Our year was highlighted by new stra

HACKENSACK, NJ / ACCESSWIRE / March 11, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery and development through data-driven research strategies and innovative pharmacology, biomarker and data platforms, today announced its financial results for the third fiscal quarter ended January 31, 2021. Third Quarter and Recent Highlights: Delivered record quarterly revenue of $10.8 million, an increase of 20% year over year Reported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $1.3 million Expanded Lumin Bioinformatics proprietary SaaS platform w